Core Insights - Commvault Systems, Inc. is under investigation for potential violations of federal securities laws as announced by Levi & Korsinsky [1] - The company reported a 40% growth in SaaS ARR, reaching $364 million for Q3 fiscal 2026, but this represents a deceleration from the 56% growth reported in Q2 fiscal 2026 [2] - Following the earnings report, Commvault's stock experienced a significant decline of over 31% on January 27, 2026 [3] Financial Performance - Commvault's SaaS ARR grew to $364 million, marking a 40% increase year-over-year [2] - The company noted that 60% of its deals closed in the last few weeks of the quarter, indicating a potential last-minute surge in sales [2] - The growth rate of 40% in SaaS ARR is a notable slowdown compared to the previous quarter's growth of 56% [2] Market Reaction - The stock price of Commvault fell by more than 31% on the day the financial results were announced, reflecting investor concerns over the deceleration in growth [3]

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as well as claims under Sections 11 and 15 of the Securities Act of 1933 [3]. - Investors have until March 6, 2026, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [3]. Group 2: Company Background - Fermi Inc. is an energy and AI infrastructure company aiming to build large-scale nuclear reactors to support grid-independent data centers for AI companies [4]. - The company's flagship project, Project Matador, is designed to provide dedicated power for AI workloads [4]. Group 3: IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Group 4: Stock Price Impact - Following the announcement that the First Tenant terminated the Advance in Aid of Construction Agreement, Fermi's stock dropped by $5.16 per share, over 33%, from $15.25 to $10.09 on December 12, 2025 [7].

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and its senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][3]. Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partners like Core Scientific for development [4]. Allegations of Securities Fraud - The lawsuit claims that CoreWeave misrepresented its ability to meet customer demand and concealed construction delays at its data centers, despite assurances of capitalizing on strong demand and competitive strengths [5]. Stock Performance and Impact - On October 30, 2025, CoreWeave's stock dropped by $8.87 (over 6%) after Core Scientific failed to secure enough shareholder votes for a merger, leading to the termination of the merger agreement [6]. - Following a revenue guidance cut on November 10, 2025, due to delays from a third-party developer, the stock fell by $17.22 (over 16%) [7]. - A report on December 15, 2025, regarding further delays in a major data center project led to an additional drop of $2.85 (over 3%) in stock price [8].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Denha v. BellRing Brands, Inc., No. 1:26-cv-00575 [2]. - Investors have until March 23, 2026, to request to be appointed to lead the case [2]. Group 2: Company Background - BellRing Brands develops, markets, and sells "convenient nutrition" products, primarily known for its ready-to-drink protein shakes under the Premier Protein brand [3]. - The company previously claimed that its sales growth was due to increased consumer demand and various positive factors, while downplaying competitive pressures [3]. Group 3: Stock Performance and Impact - On May 6, 2025, BellRing's CFO indicated that several key retailers had reduced their inventory levels, leading to a projected mid-single-digit headwind for Q3 growth, resulting in a stock price drop of $14.88 per share, or 19% [4]. - Following the announcement of narrowed fiscal year 2025 sales outlook on August 4, 2025, the stock dropped by $17.46 per share, nearly 33%, from $53.64 to $36.18 [5][6].

Core Viewpoint - A class action lawsuit has been filed against Fermi Inc. and its executives due to significant stock price drops linked to potential violations of federal securities laws [1][3]. Company Overview - Fermi Inc. is an energy and AI infrastructure company focused on building large-scale nuclear reactors to support grid-independent data centers for AI workloads [4]. - The company's flagship project is Project Matador, designed to provide dedicated power for AI operations [4]. IPO and Allegations - Fermi completed its IPO in October 2025, claiming strong demand for Project Matador and securing a 20-year lease with an investment-grade-rated tenant [5]. - Allegations suggest that Fermi overstated tenant demand and misrepresented the agreement with the First Tenant [6]. Stock Performance - Following the announcement that the First Tenant terminated the Advance in Aid of Construction Agreement, Fermi's stock dropped by $5.16, or over 33%, from $15.25 to $10.09 per share on December 12, 2025 [7].

Core Points - A class action lawsuit has been filed against CoreWeave, Inc. and certain senior executives for securities fraud following significant stock drops due to potential violations of federal securities laws [1][3] - Investors are encouraged to seek additional information regarding the lawsuit and their legal options [2][9] Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure, relying on partners like Core Scientific for development [4] - The company announced a merger agreement with Core Scientific on July 7, 2025 [4] Allegations and Stock Performance - CoreWeave allegedly overstated its ability to meet customer demand and concealed significant construction delays at its data centers, despite assuring investors of its competitive strengths [5] - The stock price dropped significantly following key events: - On October 30, 2025, the termination of the merger agreement led to a drop of $8.87 per share (over 6%) from $139.93 to $131.06 [6] - On November 10, 2025, lowered guidance for revenue and capacity due to construction delays caused a drop of $17.22 per share (over 16%) from $105.61 to $88.39 [7] - On December 15, 2025, reports of further delays in a major data center project resulted in a drop of $2.85 per share (over 3%) from $72.35 to $69.50 [8]

Core Viewpoint - Kirby McInerney LLP is investigating potential securities fraud claims against ICON Public Limited Company due to concerns over accounting practices and internal controls, particularly regarding revenue recognition from fiscal years 2023 to 2025 [1] Group 1: Investigation Details - The investigation is focused on whether ICON and/or its senior management violated federal securities laws or engaged in unlawful business practices [1] - ICON's Audit Committee is currently conducting an investigation into certain accounting practices and internal controls [1] - The company has indicated that it expects to report one or more material weaknesses in internal control over financial reporting [1] Group 2: Financial Impact - Following the announcement of the investigation, ICON's share price fell by $53.06, approximately 40%, from $133.14 on February 11, 2026, to close at $80.08 on the same day [1] - ICON has delayed the release of its fourth quarter and full year 2025 financial results and has withdrawn its previously issued 2025 guidance [1]

Core Viewpoint - A class action lawsuit has been filed against CoreWeave, Inc. and its executives, alleging that they misled investors about the company's ability to scale its AI infrastructure and meet revenue guidance [1][3]. Allegations of Misrepresentation - The lawsuit claims that CoreWeave overstated its capacity to meet strong customer demand while downplaying operational risks associated with reliance on a single third-party data center supplier [2][8]. - Significant delays at the Denton, Texas data center, which were revealed to be months behind schedule, contributed to a market capitalization loss of approximately $14 billion [2][8]. Market Reaction - Following the company's lowered revenue guidance, CoreWeave's stock experienced a 16% drop on November 11, 2025, and further declines occurred after the Wall Street Journal report on construction delays, resulting in billions in lost shareholder value [8]. Legal Proceedings - Hagens Berman is actively advising investors who purchased CoreWeave shares between March 28, 2025, and December 15, 2025, and who suffered significant losses [4]. - The deadline for lead plaintiffs to submit their claims is set for March 13, 2026 [5].

NEW YORK--(BUSINESS WIRE)---- $ORCL #AI--Oracle Corporation Sued for Securities Fraud after 11% Stock Drop -- Investors Notified to Contact BFA Law by April 6 Class Action Deadline. ...

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals for alleged violations of securities laws due to misleading statements regarding its manufacturing capabilities and regulatory submissions [1][4]. Group 1: Lawsuit Details - The Schall Law Firm is representing investors in a class action lawsuit against Inovio Pharmaceuticals for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Inovio's securities between October 10, 2023, and December 26, 2025, are encouraged to participate in the lawsuit before the deadline of April 7, 2026 [2]. - The lawsuit claims that Inovio made false and misleading statements about its CELLECTRA device and the likelihood of filing the INO-3107 Biologics License Application (BLA) by the second half of 2024 [4]. Group 2: Allegations Against Inovio - The complaint alleges that Inovio suffered from manufacturing deficiencies and failed to provide sufficient evidence for an FDA priority review or accelerated approval for its BLA [4]. - As a result of these misleading statements, investors experienced damages when the truth about Inovio's situation was revealed [4].